Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
Martens CR, Denman BA, Mazzo MR, et al.
Key finding
NR at 1 g/day raises NAD+ ~60% and may reduce systolic BP in adults with Stage 1 hypertension. Source: Martens CR, Denman BA, Mazzo MR, et al. Nature Communications, 2018.
Summary
6-week crossover trial of 1 g/day NR in middle-aged and older adults. Raised NAD+ ~60% and reduced systolic blood pressure in a subgroup with elevated baseline BP.
For background on the compound studied here, see our NR precursor reference.
Frequently asked questions
- What did Martens et al. (2018) find about NR?
- NR at 1 g/day raises NAD+ ~60% and may reduce systolic BP in adults with Stage 1 hypertension. Source: Martens CR, Denman BA, Mazzo MR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nature Communications, 2018.
- What kind of study is Martens 2018?
- It is a clinical trial on NR published in Nature Communications in 2018. 6-week crossover trial of 1 g/day NR in middle-aged and older adults. Raised NAD+ ~60% and reduced systolic blood pressure in a subgroup with elevated baseline BP.
- Where can I read the full Martens 2018 paper?
- The primary source is available on PubMed (PMID 29599478) and via DOI 10.1038/s41467-018-03421-7.
Access the full paper
Related research
Nature Communications · 2016
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
NR is orally bioavailable in humans and raises blood NAD+ without flushing.
Cell Reports · 2019
Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome
NR raises tissue NAD+ in aged muscle and shifts mitochondrial transcription.
Scientific Reports · 2019
Safety and metabolism of long-term administration of NIAGEN (Nicotinamide Riboside Chloride) in healthy middle-aged and older adults
NR is well tolerated at doses up to 1 g/day over 8 weeks in healthy adults.